Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review

Research output: Contribution to journalReviewResearchpeer-review

Standard

Postembolization Syndrome after Prostatic Artery Embolization : A Systematic Review. / Svarc, Petra; Taudorf, Mikkel; Nielsen, Michael Bachmann; Stroomberg, Hein Vincent; Røder, Martin Andreas; Lönn, Lars.

In: Diagnostics, Vol. 10, No. 9, 659, 2020.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Svarc, P, Taudorf, M, Nielsen, MB, Stroomberg, HV, Røder, MA & Lönn, L 2020, 'Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review', Diagnostics, vol. 10, no. 9, 659. https://doi.org/10.3390/diagnostics10090659

APA

Svarc, P., Taudorf, M., Nielsen, M. B., Stroomberg, H. V., Røder, M. A., & Lönn, L. (2020). Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. Diagnostics, 10(9), [659]. https://doi.org/10.3390/diagnostics10090659

Vancouver

Svarc P, Taudorf M, Nielsen MB, Stroomberg HV, Røder MA, Lönn L. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. Diagnostics. 2020;10(9). 659. https://doi.org/10.3390/diagnostics10090659

Author

Svarc, Petra ; Taudorf, Mikkel ; Nielsen, Michael Bachmann ; Stroomberg, Hein Vincent ; Røder, Martin Andreas ; Lönn, Lars. / Postembolization Syndrome after Prostatic Artery Embolization : A Systematic Review. In: Diagnostics. 2020 ; Vol. 10, No. 9.

Bibtex

@article{fe00dc6a310840f7a0b45c368a0c2c64,
title = "Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review",
abstract = "Postembolization syndrome (PES) is the most common side effect of vascular embolization of solid organs. The aim of this review was to determine the incidence of PES and its individual components after prostatic artery embolization (PAE). A systematic review with a pre-specified search strategy for PubMed, Embase, Web of Science and Cochrane Library was performed according to PRISMA guidelines. Studies in English regarding PAE in humans with 10 or more participants were eligible for inclusion. No restrictions on participant demographics or PAE technique were imposed. The search returned 378 references, of which 32 studies with a total of 2116 patients met the inclusion criteria. The results for overall PES frequency and individual PES components were presented as median (interquartile range, (IQR)). Overall median PES frequency was 25.5% (12.5–45.8). The two most frequent individual PES components were dysuria/urethral burning and local pain, with a median frequency of 21.7% (13.8–33.3) and 20% (5.4–29.4), respectively. Most outcome measures were characterized by a marked lack of uniformity and inconsistency in reporting across studies. Development of a uniform reporting system would help the clinicians recognize and treat PES accordingly.",
keywords = "Benign prostatic hyperplasia, Postembolization syndrome, Prostatic artery embolization",
author = "Petra Svarc and Mikkel Taudorf and Nielsen, {Michael Bachmann} and Stroomberg, {Hein Vincent} and R{\o}der, {Martin Andreas} and Lars L{\"o}nn",
year = "2020",
doi = "10.3390/diagnostics10090659",
language = "English",
volume = "10",
journal = "Diagnostics",
issn = "2075-4418",
publisher = "MDPI AG",
number = "9",

}

RIS

TY - JOUR

T1 - Postembolization Syndrome after Prostatic Artery Embolization

T2 - A Systematic Review

AU - Svarc, Petra

AU - Taudorf, Mikkel

AU - Nielsen, Michael Bachmann

AU - Stroomberg, Hein Vincent

AU - Røder, Martin Andreas

AU - Lönn, Lars

PY - 2020

Y1 - 2020

N2 - Postembolization syndrome (PES) is the most common side effect of vascular embolization of solid organs. The aim of this review was to determine the incidence of PES and its individual components after prostatic artery embolization (PAE). A systematic review with a pre-specified search strategy for PubMed, Embase, Web of Science and Cochrane Library was performed according to PRISMA guidelines. Studies in English regarding PAE in humans with 10 or more participants were eligible for inclusion. No restrictions on participant demographics or PAE technique were imposed. The search returned 378 references, of which 32 studies with a total of 2116 patients met the inclusion criteria. The results for overall PES frequency and individual PES components were presented as median (interquartile range, (IQR)). Overall median PES frequency was 25.5% (12.5–45.8). The two most frequent individual PES components were dysuria/urethral burning and local pain, with a median frequency of 21.7% (13.8–33.3) and 20% (5.4–29.4), respectively. Most outcome measures were characterized by a marked lack of uniformity and inconsistency in reporting across studies. Development of a uniform reporting system would help the clinicians recognize and treat PES accordingly.

AB - Postembolization syndrome (PES) is the most common side effect of vascular embolization of solid organs. The aim of this review was to determine the incidence of PES and its individual components after prostatic artery embolization (PAE). A systematic review with a pre-specified search strategy for PubMed, Embase, Web of Science and Cochrane Library was performed according to PRISMA guidelines. Studies in English regarding PAE in humans with 10 or more participants were eligible for inclusion. No restrictions on participant demographics or PAE technique were imposed. The search returned 378 references, of which 32 studies with a total of 2116 patients met the inclusion criteria. The results for overall PES frequency and individual PES components were presented as median (interquartile range, (IQR)). Overall median PES frequency was 25.5% (12.5–45.8). The two most frequent individual PES components were dysuria/urethral burning and local pain, with a median frequency of 21.7% (13.8–33.3) and 20% (5.4–29.4), respectively. Most outcome measures were characterized by a marked lack of uniformity and inconsistency in reporting across studies. Development of a uniform reporting system would help the clinicians recognize and treat PES accordingly.

KW - Benign prostatic hyperplasia

KW - Postembolization syndrome

KW - Prostatic artery embolization

U2 - 10.3390/diagnostics10090659

DO - 10.3390/diagnostics10090659

M3 - Review

C2 - 32878325

AN - SCOPUS:85090752774

VL - 10

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 9

M1 - 659

ER -

ID: 249949887